ELAB - CIK 0001840563
Elevai Labs Inc. trades as ELAB. In its fiscal 2025 annual report the company posted revenue of $590.08K, down 65.5% from the prior year and net income of -$7.75M. This page tracks Elevai Labs Inc. through 252 SEC filings, with financial statements and metrics updated as new reports are filed.
Net profit margin compressed from -234.9% to -1313.0% over the same period - every figure below comes from the company's audited annual filings.
| Filing | Type | Filed |
|---|---|---|
| SCHEDULE 13G/A | - | 2026-05-27 |
| Proxy statement | DEF 14A | 2026-05-15 |
| Quarterly report | 10-Q | 2026-05-15 |
| Major company event | 8-K | 2026-05-13 |
| PRE 14A | - | 2026-05-04 |
| DEF 14C | - | 2026-05-04 |
| Major company event | 8-K | 2026-04-28 |
| DEF 14C | - | 2026-04-27 |
The largest companies sharing Elevai Labs Inc.'s SEC industry classification (pharmaceutical preparations).
Elevai Labs Inc. reported revenue of $590.08K for fiscal year 2025, a decrease of 65.5% year over year.
In its latest fiscal year Elevai Labs Inc. reported a net loss of $7.75M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.